Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029581 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
A Phase 2 study of Lewy Body Dementia Psychosis, sponsored by ACADIA Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT07029581 is a Phase 2 study of Lewy Body Dementia Psychosis that is actively recruiting participants, run by ACADIA Pharmaceuticals. The registered enrollment target is 180 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT07029581, a Phase 2 study of Lewy Body Dementia Psychosis, is actively recruiting participants, sponsored by ACADIA Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ACP-204
Study Locations (20)
Florida
- Humanity Clinical Research, Corp - Aventura
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- K2 Medical Research Winter Garden LLC - Clermont
- K2 Summit Research - Lady Lake
- Neurology Associates, P. A. - Maitland
- Homestead Associates in Research Inc - Miami
- Premier Clinical Research Institute, Inc. - Miami
- Advanced Clinical Research Network, Corp - Miami
- MediClear Medical & Research Center, Inc. - Miami
- Health Synergy Clinical Research, LLC - West Palm Beach
Texas
- Horizon Clinical Research Group - Cypress
- The University of Texas Health Science Center San Antonio - San Antonio
California
- ATP Clinical Research Inc. - Irvine
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Kansas
- University of Kansas Medical Center Research Institute Inc. - Kansas City
New York
- Parkinson's Disease and Movement Disorders Center of Boca Raton d/b/a Parkinson's Research Center of America-Long Island - Commack
North Carolina
- UNC Hospitals - Chapel Hill
Ohio
- The Ohio State University, Energy Advancement and Innovation Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07029581
The ClinicalTrials.gov registry entry for NCT07029581 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lewy Body Dementia Psychosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07029581 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT07029581 about?
NCT07029581 is a clinical study titled "Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis". Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
What is the current status of trial NCT07029581?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-08-06. Estimated completion is 2028-03.
What conditions does trial NCT07029581 study?
This clinical trial studies the following conditions: Lewy Body Dementia Psychosis.
What interventions are being tested in trial NCT07029581?
The interventions under investigation include: Placebo (DRUG), ACP-204 (DRUG).
Who is sponsoring clinical trial NCT07029581?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029581 being conducted?
This trial has 20 study locations across California, Florida, Hawaii, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.